Stock code: 002653.SZ
Sishujing® (Anrikefon Injection)
Sishujing® (Anrikefon Injection) is the world's first highly selective peripheral kappa opioid receptor agonist approved for analgesic indications. It was approved for marketing in May 2025 for the treatment of mild to moderate pain following abdominal surgery and for adult patients with moderate to severe pruritus associated with chronic kidney disease on maintenance hemodialysis.
[1] Package Insert of Anrikefon Injection.
[2] Guideline for Perioperative Pain Management in Patients Undergoing Abdominal Surgery (2025 Edition).
[3] A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Anrikefon Injection for postoperative analgesia in subjects undergoing elective abdominal laparoscopic surgery under general anesthesia (Study No.: NCT04738357)
[4] A multicenter, randomized, double-blind, placebo/active-controlled Phase III clinical study to evaluate the efficacy and safety of Anrikefon Injection for the treatment of postoperative pain (Study No.: NCT05390905)
Download prescribing information
Analgesic and Antipruritic Effects
No Central Nervous System Risks
Gastrointestinal Comfort and Mildness
Minimal Hepatic and Renal Burden
Eighteen related academic papers have been published, including in Nature Communications and The BMJ, etc; study findings have been presented 4 times at top global academic conferences such as American Society of Nephrology (ASN), European Society of Anaesthesiology (ESA), and Japanese Society of Anesthesiologists (JSA), showcasing Chinese original analgesic and antipruritic drug study results to the world; it has been formally incorporated into 3 authoritative guidelines and expert consensus statements, including the Clinical Practice Guideline for Postoperative Pain Management in Adults (2024 Edition) and the Guideline for Perioperative Pain Management in Abdominal Surgery (2025 Edition), etc.
What is the target of Sishujing® (Anrikefon)?
It is a highly selective peripheral kappa opioid receptor agonist.
What is the innovative status of Sishujing® (Anrikefon) in the field of analgesia?
It is the world's first highly selective peripheral kappa opioid receptor agonist approved for an analgesic indication.
In which year was Sishujing (Anrikefon) approved for marketing?
The indications for pain following abdominal surgery and for pruritus associated with chronic kidney disease were approved in May and September 2025, respectively.
What is the indication of Sishujing® (Anrikefon) in postoperative pain management?
It is indicated for the treatment of mild to moderate pain following abdominal surgery.
What is the indication of Sishujing® (Anrikefon) in chronic kidney disease?
It is indicated for adult patients with moderate to severe pruritus associated with chronic kidney disease on maintenance hemodialysis.
Does Sishujing® (Anrikefon) cause central nervous system side effects such as addiction?
It hardly crosses the blood-brain barrier, effectively avoiding central nervous system adverse reactions such as respiratory depression and addiction.
Can Sishujing® (Anrikefon) reduce postoperative nausea and vomiting?
Yes. Its peripheral mechanism of action provides good gastrointestinal safety, effectively reducing the risk of postoperative nausea and vomiting. Clinical studies have shown that its incidence of postoperative nausea and vomiting is lower than that of placebo.
Is Sishujing® (Anrikefon) metabolized by the liver?
It is seldom metabolized by the liver.
Which special populations are suitable for Sishujing® (Anrikefon)?
No dose adjustment of Anrikefon is required for patients with hepatic insufficiency or mild to moderate renal insufficiency. For patients with severe renal insufficiency, a reduction of the Anrikefon dose by half is recommended. For elderly patients, no dose adjustment based on age is required.
As of May 2026, how many academic papers on Sishujing® (Anrikefon) have been published?
Eighteen related academic papers have been published.
In which top journals have studies on Sishujing® (Anrikefon) been published?
Core data have been published in top journals such as The BMJ and Nature Communications.
As of May 2026, which top international medical conferences has Sishujing® (Anrikefon) been presented at?
It has been presented 4 times at international academic conferences such as American Society of Nephrology (ASN), European Society of Anaesthesiology (ESA), and Japanese Society of Anesthesiologists (JSA), etc.
What has Sishujing® (Anrikefon) showcased at international conferences?
It has comprehensively and systematically showcased the clinical study achievements of China's original analgesic and antipruritic drug to the world.
As of May 2026, how many authoritative guidelines have included Sishujing® (Anrikefon)?
It has been formally included in 3 authoritative guidelines and expert consensus statements.
Which specific pain management guidelines include Sishujing® (Anrikefon)?
They include the Chinese Clinical Practice Guideline for Adult Postoperative Pain Management (2024 Edition) and the Guideline for Perioperative Pain Management in Abdominal Surgery (2025 Edition), etc.
Has Sishujing® (Anrikefon) been included in the National Reimbursement Drug List?
Yes. It underwent its first medical insurance negotiation in 2025 and was successfully included in the National Reimbursement Drug List in 2026.
As of May 2026, what is the current coverage of Sishujing® (Anrikefon) in medical institutions?
It is currently used in 300+ key medical institutions nationwide.
What are the core pharmacological advantages of Sishujing® (Anrikefon)?
By specifically activating peripheral kappa opioid receptors, it provides potent analgesic and antipruritic effects while significantly improving central nervous system and gastrointestinal safety.
Is Sishujing® (Anrikefon) an original innovative drug?
Yes, it is an innovative drug developed in China with independent intellectual property rights and high recognition from domestic and international academic communities.
What are the outstanding advantages of Sishujing® (Anrikefon) in postoperative analgesia?
It provides potent analgesia while avoiding central nervous system adverse reactions such as respiratory depression and addiction. It also has good gastrointestinal safety, reducing postoperative nausea and vomiting. In addition, it is seldom metabolized by the liver, making it safer for special populations such as the elderly and patients with hepatic insufficiency.
